HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper.
Analytical treatment interruption (ATI) COVID-19
HIV cure
SARS-CoV-2
Journal
Journal of virus eradication
ISSN: 2055-6640
Titre abrégé: J Virus Erad
Pays: England
ID NLM: 101654142
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
18
10
2020
revised:
04
12
2020
accepted:
04
12
2020
pubmed:
15
12
2020
medline:
15
12
2020
entrez:
14
12
2020
Statut:
ppublish
Résumé
This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.
Identifiants
pubmed: 33312681
doi: 10.1016/j.jve.2020.100025
pii: S2055-6640(20)31474-6
pmc: PMC7719279
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100025Subventions
Organisme : Medical Research Council
ID : MR/L006588/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P011233/1
Pays : United Kingdom
Informations de copyright
© 2020 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The co-authors of this manuscript have no conflicts of interest to declare.
Références
AIDS Res Hum Retroviruses. 2020 Apr;36(4):260-267
pubmed: 31608648
AIDS. 2020 Oct 1;34(12):1781-1787
pubmed: 32604138
Clin Infect Dis. 2020 Aug 29;:
pubmed: 32860699
Nat Med. 2016 Aug;22(8):839-50
pubmed: 27400264
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350047
Clin Infect Dis. 2020 Dec 31;71(11):2933-2938
pubmed: 32594164
Ethics Hum Res. 2019 Nov;41(6):23-34
pubmed: 31743627
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
PLoS One. 2013 Oct 25;8(10):e78287
pubmed: 24205183
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):245-251
pubmed: 31343455
J Antimicrob Chemother. 2019 Jul 1;74(7):2039-2046
pubmed: 31225610
J Infect Dis. 2021 Feb 13;223(3):403-408
pubmed: 32601704
HIV Med. 2020 Oct;21(9):567-577
pubmed: 32671970
AIDS. 2019 Jul 1;33(8):1335-1344
pubmed: 31157663
PLoS Pathog. 2013 Feb;9(2):e1003174
pubmed: 23459007
Immunity. 2013 Oct 17;39(4):633-45
pubmed: 24138880
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Ann Intern Med. 2020 Oct 6;173(7):536-541
pubmed: 32589451
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7
pubmed: 9371822
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
Sci Rep. 2017 Oct 20;7(1):13658
pubmed: 29057945
N Engl J Med. 1998 Mar 26;338(13):853-60
pubmed: 9516219
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
J Int AIDS Soc. 2017 Jan 12;20(1):21188
pubmed: 28364566
Lancet HIV. 2019 Apr;6(4):e259-e268
pubmed: 30885693
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
Curr Trop Med Rep. 2020 Mar 3;:1-4
pubmed: 32219057
J Acquir Immune Defic Syndr. 2020 Sep 1;85(1):6-10
pubmed: 32568770
Int J Environ Res Public Health. 2020 Jun 24;17(12):
pubmed: 32599783
Can J Cardiol. 2019 Mar;35(3):238-248
pubmed: 30825947
J Med Virol. 2021 Jan;93(1):170-171
pubmed: 32633849
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185